Following the announced sale of SomaLogic, Inc. (“SomaLogic”) and other specified assets to Illumina, Inc. (“Illumina”) in June 2025, all financial results in this section reflect continuing ...
Standard BioTools Inc (NASDAQ:LAB) is set to release its Q2 2025 earnings on August 11, 2025. The consensus estimate for Q2 2025 revenue is $39.82 million, and the earnings are expected to come in at ...
BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended ...
Standard BioTools Inc. will release its first quarter 2025 financial results on May 6, 2025, after market close, and will host a conference call and webcast at 4:30 p.m. ET that same day to discuss ...
Standard BioTools reports preliminary 2024 revenue of $174 million and will present at the J.P. Morgan Healthcare Conference. Standard BioTools Inc. announced preliminary, unaudited revenue results ...
Standard BioTools expects the restructuring costs to be paid over the next several months. The company indicated that the operational changes are intended to support the execution of its long-term ...
In other recent news, Standard BioTools Inc. has announced significant changes as part of a restructuring plan aimed at improving operational efficiency. The company has initiated a reduction of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results